Literature DB >> 3121667

Disk diffusion susceptibility testing and broth microdilution quality control guidelines for BMY-28100, a new orally administered cephalosporin.

R N Jones1, A L Barry.   

Abstract

The BMY-28100 30-micrograms-disk test was evaluated by using 615 clinical isolates. Regression analyses and error rates were determined, leading to the recommendation of greater than or equal to 18-mm zone diameters (MIC correlate, greater than or equal to 8.0 micrograms/ml) for susceptibility and less than or equal to 14-mm zone diameters (MIC correlate, greater than or equal to 32 micrograms/ml) for resistance. Nearly all false-susceptible disk test results were among the Providencia spp. and the beta-lactamase-positive Haemophilus influenzae strains. Susceptibility disk test results for these species should be interpreted with caution. The following broth microdilution MIC quality control guidelines were determined from results of a multilaboratory trial: Escherichia coli ATCC 25922, 1.0 to 4.0 micrograms/ml; Enterococcus faecalis ATCC 29212, 4.0 to 16 micrograms/ml; Staphylococcus aureus ATCC 29213, 0.25 to 1.0 microgram/ml; and Pseudomonas aeruginosa ATCC 27853, greater than 32 micrograms/ml.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3121667      PMCID: PMC269444          DOI: 10.1128/jcm.25.11.2211-2213.1987

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  12 in total

1.  In vitro activity of BMY-28100 against common isolates from pediatric infections.

Authors:  R K Scribner; M I Marks; B D Finkhouse
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

2.  Susceptibility tests of anaerobic bacteria: statistical and clinical considerations.

Authors:  C M Metzler; R M DeHaan
Journal:  J Infect Dis       Date:  1974-12       Impact factor: 5.226

3.  Comparative antibacterial activity of a new oral cephalosporin, BMY-28100.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

4.  In vitro activity of BMY 28100, a new oral cephalosporin.

Authors:  J Steele; B Edwards; J Rissing
Journal:  Eur J Clin Microbiol       Date:  1987-02       Impact factor: 3.267

5.  In vitro activity of BMY-28100, a new oral cephalosporin.

Authors:  G M Eliopoulos; E Reiszner; C Wennersten; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

6.  Quality control limits for microdilution susceptibility tests with aztreonam, imipenem, ceftriaxone, ceftazidime, ceftizoxime, cefuroxime, and cefonicid.

Authors:  A L Barry; T L Gavan; R N Jones; L W Ayers; P C Fuchs; E H Gerlach; C Thornsberry
Journal:  Diagn Microbiol Infect Dis       Date:  1987-05       Impact factor: 2.803

7.  Comparison of the antibacterial spectra of cephalexin and cefaclor with those of cephalothin and newer cephalosporins: reevaluation of the class representative concept of susceptibility testing.

Authors:  D A Preston; R N Jones; A L Barry; C Thornsberry
Journal:  J Clin Microbiol       Date:  1983-06       Impact factor: 5.948

8.  Cefixime disk susceptibility test criteria.

Authors:  P C Fuchs; A L Barry; R N Jones
Journal:  J Clin Microbiol       Date:  1986-10       Impact factor: 5.948

9.  Cefadroxil, a new broad-spectrum cephalosporin.

Authors:  R E Buck; K E Price
Journal:  Antimicrob Agents Chemother       Date:  1977-02       Impact factor: 5.191

10.  In vitro activity of Ro 15-8074 and Ro 19-5247, two orally administered cephalosporin metabolites.

Authors:  R Wise; J M Andrews; L J Piddock
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

View more
  5 in total

1.  Inability of cephalothin testing to predict cefprozil susceptibility.

Authors:  J Fung-Tomc; T Stickle; C Doyle; E Huczko; R E Kessler
Journal:  J Clin Microbiol       Date:  1991-11       Impact factor: 5.948

Review 2.  Cefprozil. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic potential.

Authors:  L R Wiseman; P Benfield
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

3.  Predictive accuracy of disk diffusion test for Proteus vulgaris and Providencia species against five newer orally administered cephalosporins, cefdinir, cefetamet, cefprozil, cefuroxime, and loracarbef.

Authors:  D J Biedenbach; R N Jones
Journal:  J Clin Microbiol       Date:  1994-02       Impact factor: 5.948

4.  Interpretive accuracy of the disk diffusion method for testing newer orally administered cephalosporins against Morganella morganii.

Authors:  D J Biedenbach; R N Jones; M E Erwin
Journal:  J Clin Microbiol       Date:  1993-10       Impact factor: 5.948

5.  Disk diffusion susceptibility testing for LY163892 (KT-3777), a new orally administered 1-carbacephem.

Authors:  R N Jones; A L Barry
Journal:  J Clin Microbiol       Date:  1988-04       Impact factor: 5.948

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.